Topological models for the prediction of cyclin-dependent kinase 2 inhibitory activity of aminothiazoles

Match

Volumn , Issue 51, 2004, Pages 59-78

  Kumar, Vipin ^a   Kumar Madan, Anil ^a  

^a MAHARSHI DAYANAND UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; THIAZOLE DERIVATIVE;

ACCURACY; ARTICLE; COMPARATIVE STUDY; DATA ANALYSIS; DRUG ACTIVITY; DRUG SCREENING; ENZYME INHIBITION; INHIBITION KINETICS; MODEL; PARAMETER; PREDICTION;

EID: 9144227739     PISSN: 03406253     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Welling P. G., Lasagna L., and Banakar, U. V., The Drug Development Process: Increasing Efficiency and Cost Effectiveness, Marcel Decker, New York, 1996, pp vii-viii.
2. Basak S. C., Niemi G. J., and Veith G. D., Optimal characterization of structure for prediction of properties, J. Math. Chem. (1990) 4, 185-205.
3. Hansen P.J., and Jurs P.C., Chemical applications of graph theory, J. Chem. Educ. (1988) 65, 574-580.
4. Trinajstic N., Chemical Graph Theory, CRC Press: Boca Raton, 1983, Vol. I, pp. 31-34.
5. Hosoya H., Topological index; newly proposed quantity characterizing the topological nature of structure of isomers of saturated hydrocarbons, Bull. Chem. Soc. Jpn. (1971) 44, 2332-2337.
6. Hosoya H., Topological index as strong sorting device for coding chemical structure, J. Chem. Doc. (1972) 12, 181-183.
7. Randic M., On characterization of molecular branching. J. Am. Chem. Soc. (1974) 97, 6609-6615.
8. Kier L. B., and Hall L. H., Molecular Connectivity in Structure-Activity Analysis, Research Studies Press, Letchworth, 1986.
9. Balaban A. T., Chiriac A., Motoc I., and Simon Z., Steric fit in QSAR, Lect. Notes Chem., (1980) 15, 22-27.
10. Balaban A. T., Highly discriminating distance based topological index, Chem. Phys. Lett. (1982) 89, 399-404.
11. Balaban A. T., Applications of graph theory in chemistry, J. Chem. Inf. Comput. Sci. (1985) 25, 334-343.
12. Balaban A. T., and Quinar L. B., The smallest graphs, trees and 4-trees with degenerate topological index, J. Math. Chem. (1983) 14, 163-233.
13. Wiener H., Influence of interatomic forces on paraffin properties, J. Chem. Phys., (1974) 15, 766-766.
14. Wiener H., Correlation of heat of isomerization and difference in heat of vaporization of isomers among paraffin hydrocarbons, J. Am. Chem. Soc. (1947) 69, 2636-2638.
15. Randic M., Guo X., Oxely T., and Krishnapriyan H., Wiener matrix; source of novel graph invariants, J. Chem. Inf. Comput. Sci. (1993) 33, 709-716.
16. Gutman I., and Randic M., Algebric characterization of skeletal branching, Chem. Phys. Lett. (1977) 47, 15-19.
17. Gutman I., Ruscic B., Trinajstic N., and Wicox C. F., Graph theory and molecular orbitals.XII. Acyclic polyenes, J. Chem. Phys. (1975) 62, 3399-3405.
18. Sharma V., Goswami R., and Madan A. K., Eccentric connectivity index: A novel highly discriminating topological descriptor for structure property and structure activity studies, J. Chem. Inf. Comput. Sci. (1997) 37, 273-282.
19. Gupta S., Singh M., and Madan A. K., Application of graph theory: Relationship of eccentric connectivity index and Wiener's index with anti-inflammatory activity, J. Math. Anal. Applic. (2002) 266, 259-268.
20. Sardana S., and Madan A. K., Application of graph theory: Relationship of antimycobacterial activity of quinolone derivatives with eccentric connectivity index and Zagreb group parameter, MATCH Commun. Math. Comput. Chem. (2002) 45, 36-53.
21. Sardana S., and Madan A. K., Application of graph theory: Relationship of molecular connectivity index, Wiener's index and eccentric connectivity index with diuretic activity, MATCH Commun. Math. Comput. Chem. (2001) 45, 36-53.
22. Dobashi Y., Takehana T., and Ooi A., Perspectives on cancer therapy: cell cycle blockers and perturbators, Curr. Med. Chem. (2003) 10, 2549-2558.
23. Fischer P. M., Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors, Curr. Opin. Drug Discov. Devel. (2001) 4, 623-634.
24. Pines J., The cell cycle kinases, Semin. Cancer Biol. (1994) 5, 305-313.
25. Sherr C., Cancer cell cycles, Science (1996) 274, 1672-1674.
26. Hunter T., and Pines J., Cyclins and cancer II: Cyclins and CDK inhibitors come of age, Cell (1994) 79, 573-582.
27. Lenobel R., Havli L., Kryscaron P.V., Otyepka M., and Strnad M., Olomoucine ii, new effective CDK inhibitor with strong cytotoxic properties, Scientific World J. (2001) 1 (Suppl 3), 128.
28. Pines J., Cyclins, CDKs and Cancer, Semin. Cancer Biol. (1995) 6, 63-72.
29. Hartwell L. H., and Kastan M. B., Cell cycle control and cancer, Science (1994) 266, 1821-1828.
30. Gladden A. B., and Diehl J. A, Cell cycle progression without cyclin E/CDK2. Breaking down the walls of dogma, Cancer Cell (2003) 4, 160-162.
31. Paulovich A. G., Toczyski D. P., and Hartwell L. H., When checkpoint fails, Cell (1997) 88, 315-321.
32. Pardee A. B., A restriction point for control of normal animal cell proliferation, Proc. Natl. Acad. Sci. U. S. A. (1974) 71, 1286-1290.
33. Grant S., and Roberts J. D., The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy, Drug Resist. Updat. (2003) 6, 15-26.
34. Kim K. S., Kimball D. S., Misra R. N., Rawlins D. B., Hunt J. T., Xiao H. Y., Lu S., Qian L., Han W. C., Shan W., Mitt M., Cai Z. W., Poss M. A., Zhu H., Sack J. S., Tokarski J. S., Chang C. Y., Pavletich N., Kamath A., Humphreys W. G., Marathe P., Bursuker I., Keller K. A., Roongta U., Batorsky R., Mulheron J. G., Bol D., Fairchild C. R., Lee F. Y., and Webster K. R., Discovery of aminothiazole inhibitors of cyclin-dependant kinase 2: synthesis, X-ray crystallographic analysis and biological activities, J. Med. Chem. (2002) 45, 3905-3927.
35. Gupta S., Singh M., and Madan A. K., Predicting anti-HIV activity: Computational approach using a novel topological descriptor, J. Comput. Aid. Mol. Des. (2001) 15, 671-678.
36. Martin Y. C., Quantitative Drug Design, Marcel Decker, New York, 1978.
37. Ruetz S., Fabbro D., Zimmermann J., Meyer T., and Gray N., Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors. Curr. Med. Chem. Anti-Canc. Agents (2003) 3, 1-14.